Baidu
map

IBM Watson将“狙击”癌症、糖尿病、眼疾、脑疾及心脏病等重大疾病

2016-07-22 佚名 动脉网

IBM日前宣布,公司已成立了IBM Watson Health医学影像协作计划,这是一项全球协作,共由超过15家著名的卫生机构、学院医疗中心、影像诊断供应商和医学影像技术公司组成,旨在将认知影像技术应用到医疗机构的日常工作中,帮助医生诊断乳腺癌、肺癌及其他癌症,以及糖尿病、眼疾、脑疾、心脏病及其相关病症,如中风。协作计划的成员使用IBM Watson从以前“看不见的”非结构化影像数据中提取洞察,并

IBM日前宣布,公司已成立了IBM Watson Health医学影像协作计划,这是一项全球协作,共由超过15家著名的卫生机构、学院医疗中心、影像诊断供应商和医学影像技术公司组成,旨在将认知影像技术应用到医疗机构的日常工作中,帮助医生诊断乳腺癌、肺癌及其他癌症,以及糖尿病、眼疾、脑疾、心脏病及其相关病症,如中风。

协作计划的成员使用IBM Watson从以前“看不见的”非结构化影像数据中提取洞察,并将其与其他来源的大量数据结合起来,从而帮助医生针对具体病患做出个性化治疗决策,同时创建知识库来造福更多病患。此类信息中可能包括IBM Watson从电子病历、放射影像报告和病理报告、化验结果、医生病程记录、医学文献、临床医护指南及公开的结论性报告中提取的数据。

协作计划的主要会员包括:Agfa HealthCare、Anne Arundel Medical Center、Baptist Health South Florida、Eastern Virginia Medical School、Hologic, Inc.、Ifa systems AG、Inoveon、Radiology Associates of South Florida、Sentara Healthcare、Sheridan Healthcare、Topcon、UC San Diego Health、University of Miami Health System、University of Vermont Health Network、MEDNAX附属公司vRad,以及IBM子公司Merge Healthcare。随着协作的深入,这些企业和机构的最新成果与智慧结晶定能推动IBM Watson不断提高基本能力与洞察。

根据最初计划,将对IBM Watson展开训练并评估可在各类病患护理环境中使用的潜在新产品,从单独的流动性装备到集成式医疗服务交付网络,以基于支持循证医学的证据(real-world experience)来收集数据并共享分析结果,帮助医疗机构了解如何消除运营和财务效率不高的问题、改进医生工作流程、采用以病患为中心的方法来改善护理、提高疗效。此外,医学专家还可考量如何帮助将IBM Watson集成到该计划中的医学影像技术公司的现有医疗IT系统中。例如,把IBM Watson能力与电子病历和PACS(Picture Archiving and Communication Systems,图片存档与通信系统)结合、纳入现有临床工作流程中,给医疗机构提供认知洞察。

Frost & Sullivan咨询公司医学影像与情报分析师Nadim Michel Daher表示:“像IBM Watson这样的系统在帮助放射科医师提高工作效率、诊断准确性、决策明智性及成本可管理性等方面拥有巨大潜力。此类协作项目正好能从真实世界中收集证据和案例,以推动医学成像领域实现发展进步,并在那些疾病多发国家满足病患护理需求。”

IBM Watson Health旨在帮助医疗卫生专业机构提高对医学影像数据的利用率,同时提供认知产品和服务来帮助医生提高基于每名病患的特殊需求定制治疗方案的能力,从而提高医护水平。

Anne Le Grand女士近期以IBM Watson Health影像事业副总裁身份加盟IBM,在构建同时涵盖成像、情报、诊断和专业服务等业务领域的跨国企业方面拥有超过30年的丰富经验。她表示:“认知计算云可从大量的集成式结构化与非结构化数据中提取洞察,从而改变临床医生诊断、治疗和监控病人的方式。通过IBM新成立的医学影像协作计划,IBM Watson可能使临床医生有机会从影像数据中提取更加深入的洞察和价值,同时更好地管理成本。”

IBM Watson的影像数据分析能力如何能帮医疗卫生机构实现医护转型

计划成员有望与IBM Watson医疗事业部的认知计算专家合作,训练IBM Watson帮助治疗心血管疾病、眼及其他疾病。以人口数据为基础的疾病登记数据库中包含数百万个来自世界各地的匿名案例,为帮助创建基于IBM Watson的全新解决方案,医学影像协作计划的行业会员可将IBM Watson集成到他们的工作系统或影像管理软件中。


例如,计划会员可训练IBM Watson如何及早检测出心血管疾病,并识别出常被忽略的心脏病症状,如充血性心力衰竭或心肌梗塞(心脏病发作,congestive heart failure or myocardial infarction)。为及早检测出疾病,IBM Watson可通过训练而对冠状动脉造影(coronary angiogram,正在跳动的心脏的视频图像)进行分析并“打分”,以供内科医生参考使用。这个分数常被称为“SYNTAX得分”,是内科医生判断病人患上冠状动脉疾病(coronary artery disease)、对其实施微创支架手术或搭桥手术的主要依据之一。

对于常被忽略的心脏病症状,IBM Watson可通过训练来“了解”哪些症状意味着病人心脏开始衰竭并时刻监视病情发展,从而及早发现充血性心力衰竭。

此外,IBM Watson还能帮助内科医生将各种胸痛与不同的健康问题相关联,从而判断出胸痛是否预示着可能的心脏病发作。胸痛是每年造成各大医院急诊室人满为患的主要原因,但在每年看急诊的大约700万名胸痛患者之中,高达2%的患者会因为忽视心脏病突发信号而在出院之后于家里突发心脏病。

眼部健康是该协作计划重点关注的另一个领域。参与这项工作的会员将共同致力于开发基于证据的临床决策支持系统,从而支持眼科医生和验光师开展工作。例如,他们开发的在线工具能帮眼科诊所及眼科医院从高风险人群中及早检测出并监视常见眼科疾病,例如从前去糖尿病糖尿病患者以及肥胖症或心脏病患者身上检测出糖尿病视网膜病变。

该计划还将进一步帮助IBM履行承诺,与医疗卫生专业人员密切合作来共同开发医疗解决方案。例如,IBM Watson for Oncology及IBM Watson Clinic Trial Matching便得益于此计划,也是其与美国癌症学会、美国糖尿病协会及美国心脏病协会的合作结晶。IBM将在米兰的Human Technopole Italy 2040科研园区附近建成首个IBM Watson Health European Center of Excellence,助力意大利政府实现宏大目标,打造推动基因组学、大数据、老龄化和营养学研究取得突破进展的国际中心。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-10-14 李东泽

    这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-09-22 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-09-11 doctorJiangchao

    继续关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-09-11 doctorJiangchao

    继续学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2017-01-09 HNYYM
  8. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-07-24 tulenzi
  9. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1991383, encodeId=43d21991383df, content=<a href='/topic/show?id=f51f1861818' target=_blank style='color:#2F92EE;'>#Watson#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18618, encryptionId=f51f1861818, topicName=Watson)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Oct 14 09:16:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148357, encodeId=908b14835e1f, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:25:18 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068192, encodeId=697320681920c, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Tue Nov 15 17:16:00 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132892, encodeId=ba8d132892db, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:15:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121980, encodeId=f909121980f0, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 07:00:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=121978, encodeId=c14d1219e8cf, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Sep 11 06:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684070, encodeId=005e16840e0fb, content=<a href='/topic/show?id=5955e2784bb' target=_blank style='color:#2F92EE;'>#眼疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72784, encryptionId=5955e2784bb, topicName=眼疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0d528030042, createdName=HNYYM, createdTime=Mon Jan 09 17:16:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489925, encodeId=c92c1489925b3, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628935, encodeId=923c1628935e2, content=<a href='/topic/show?id=c27a95e7106' target=_blank style='color:#2F92EE;'>#重大疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95771, encryptionId=c27a95e7106, topicName=重大疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95421243926, createdName=雕雕, createdTime=Sun Jul 24 01:16:00 CST 2016, time=2016-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94256, encodeId=bcba942565c, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sat Jul 23 11:25:00 CST 2016, time=2016-07-23, status=1, ipAttribution=)]
    2016-07-23 oo902

    好好学习

    0

相关资讯

IBM智慧医疗推动助力上海医疗业应对大数据挑战

12月5日,由IBM、上海市卫生局信息中心、中国数字医疗网联合举办的上海市公立医院改革研讨会在 上海召开。本次研讨会围绕上海公立医院改革新举措、上海市电子病例等级评审、大数据推动新医改等相关热点话题展开,旨在更好地落实《中共中央国务院关于深 化医药卫生体制改革的意见》精神,进一步推进卫生统计与信息化建设工作进程,促进上海市公立医院改革发展进程,提升卫生统计及信息化工作服务能力。 大数据时

IBM:预测未来5年科技动向,包括更智慧的医疗和更智慧的教室

IBM 刚刚公布了最新的未来 5 年 5 大预测。这些预测是通过对 22 万技术从业者的调查后,由 IBM 的众多实验室通力分析得出的结论。凡事预则立,最近 8 年,IBM 每年都要进行这样的预测—以便于该公司集中研发火力。 概而言之,IBM 的这 5 项预测是: —更智慧的教室 —更智慧的商店 —更智慧的医疗 —更智慧的安全 —更智慧的城市

IBM在2014年将推出个性化医疗服务的三款超级计算机

    据Business Insider网站报道,IBM表示,明年其商业合作伙伴将发布三款基于IBM超级计算机Watson的应用软件。     IBM Watson解决方案高级副总裁斯蒂芬•登(Stephen Gold)表示,明年,消费者将见到由IBM商业合作伙伴开发的三款基于Wat

Baidu
map
Baidu
map
Baidu
map